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Objective: Promoting reverse cholesterol transport (RCT) is a major atheroprotective property of HDL. The
present study explored the effect of stimulating the ﬁrst step of RCT (cholesterol efﬂux from macro-
phages) alone or in combination with stimulating the last step of RCT (fecal sterol excretion).
Methods and results: Reconstituted HDL (rHDL) was injected into wild-type mice either with or without
administration of the cholesterol absorption inhibitor ezetimibe or the bile acid sequestrant cholestyr-
amine. Single dose administration of rHDL (100 mg apoA-I/kg) resulted in an early (4 h) increase in
plasma free cholesterol levels (p < 0.001), without affecting hepatic cholesterol levels or fecal mass sterol
excretion. rHDL injection also increased [3H]cholesterol appearance in plasma at an early time-point (4 h)
after intraperitoneal administration of [3H]cholesterol-labeled mouse macrophage foam cells and fecal
radioactivity excretion indicating completed RCT was increased by 26% (p < 0.05). Ezetimibe treatment
inhibited intestinal cholesterol absorption by 74% (p < 0.01), but also the bile acid sequestrant chole-
styramine decreased cholesterol absorption signiﬁcantly (24%, p < 0.01). Consequently, ezetimibe
increased RCT 2.1-fold (p < 0.001) primarily within fecal neutral sterols, while cholestyramine increased
RCT by 3.6-fold (p < 0.001), primarily within bile acids (p < 0.001), but also within neutral sterols
(p < 0.001). However, no additive effects of both intestinal sterol uptake inhibitors were observed on top
of rHDL administration.
Conclusion: These data demonstrate that increasing the ﬁrst step of RCT by rHDL administration results in
transient cholesterol mobilization from macrophages to plasma. This effect is not further enhanced by
stimulating the last step of RCT, fecal sterol excretion.
 2013 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Epidemiological studies demonstrated that plasma levels of
high density lipoprotein (HDL) cholesterol and its major structural
apolipoprotein (apo) apoA-I confer signiﬁcant protection against
atherosclerotic cardiovascular disease (CVD) [1,2]. Additional evi-
dence for functional atheroprotection by apoA-I came from studies
in atherosclerosis-prone animal models. Overexpression of apoA-I
resulted in signiﬁcantly reduced atherosclerotic lesion formationigh density lipoprotein; LDL,
sport; NPC1L1, Niemann-Pick
.
, University Medical Center
Netherlands. Tel.: þ31 50
.
nd Ltd. All rights reserved.in all models investigated [3,4] and was even able to induce
regression of established atherosclerotic disease [5].
A major anti-atherogenic activity of apoA-I and HDL is to stim-
ulate cholesterol efﬂux from peripheral cells, most importantly
macrophage foam cells within atherosclerotic lesions, and conse-
quently reverse cholesterol transport (RCT) [1e4]. The starting
point of RCT is the efﬂux of cholesterol, which is then transported
through the plasma compartment within HDL particles back to the
liver for subsequent excretion into bile and feces [2,6e8]. Seminal
studies on the RCT pathway used adenovirus-mediated over-
expression of apoA-I to provide proof-of-principle for the impact of
HDL on overall macrophage-to-feces RCT [9].
For therapeutic purposes recently the infusion of reconstituted
HDL (rHDL), apoA-I together with phospholipids, has been sug-
gested as a novel approach to acutely decrease atherosclerotic
lesion burden and to stabilize atherosclerotic lesions [10,11]. In this
respect the therapeutic efﬁcacy of infusing rHDL has practical
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cological approaches targeting different steps of the RCT pathway.
Therefore, the aim of the present study was to test the in vivo effect
of a single dose administration of rHDL that is stimulating the ﬁrst
step of the RCT pathway (cholesterol efﬂux from cells) either
without or with the concomitant treatment with inhibitors of in-
testinal sterol absorption that are stimulating the last step of RCT
(fecal cholesterol as well as bile acid excretion).
Our data demonstrate that (i) stimulation of cholesterol efﬂux
by rHDL administration results in a rapid mobilization of choles-
terol to plasma translating into increased RCT and (ii) both ezeti-
mibe and cholestyramine signiﬁcantly enhance RCT, however,
without apparent synergistic efﬁcacy when applied together with
rHDL administration.
2. Methods
2.1. Animals
C57BL/6J control mice were purchased from Charles River (Sulz-
feld, Germany). The animals were caged in animal rooms with alter-
nating12hperiodsof light (from7.00 a.m. to7.00p.m.) anddark (from
7.00p.m. to 7.00 a.m.)withad libitum access towater andmousechow
diet (Arie Blok,Woerden, TheNetherlands).Animalexperimentswere
performed in conformity with PHS policy and in accordance with
national laws. All protocols were approved by the responsible ethics
committees of the University of Groningen or by the responsible au-
thorities of the Swiss federal animal protection. As general procedure
for all experiments, bloodwasdrawnunder isoﬂuraneanesthesia, and
animals were sacriﬁced by cervical dyslocation under isoﬂurane
anesthesia following heart puncture to obtain blood.
2.2. Preparation of reconstituted HDL (apoA-I-POPC)
Reconstituted rHDLwere prepared by the cholate dialysismethod
according to [12]with the followingmodiﬁcations. Lipids dissolved in
chloroform were dried as thin layer in a glass vessel. After resus-
pension inphosphatebufferedsaline (PBS), lipidswere rehydrated for
1 h at room temperature and mixed micelles formed by the addition
of cholate (Sigma, St. Louis, MO, USA) (1:1.35 M ratio with phospho-
lipid (palmitoyl-2-oleyl-phosphatidylcholine (POPC), Avanti Lipids,
Alabaster, AL, USA). After full clariﬁcation micelles were added to
apoA-I atamolar ratioof80:1 (POPC:apoA-I) and incubatedovernight
at 4 C. The mixture was then transferred into dialysis cassettes (10
000MWCO;ThermoScientiﬁc) andextensivelydialyzed for twodays.
Theprotein contentof rHDLwasquantiﬁedbyUVabsorptionusing an
extinction coefﬁcient of 1.15 l g1 cm1.
2.3. In vivo reverse cholesterol transport studies
Wild-type C57BL/6J donor mice were injected intraperitoneally
with 0.5 ml of 10% Brewer thioglycollate medium (Becton Dickinson,
Le Pont de Claix, France). On day 4 after thioglycollate injection,
peritoneal macrophages were harvested, cultured and loaded with
50 mg/ml acetylated low density lipoprotein (LDL) and 3 mCi/ml [3H]
cholesterol (Perkin Elmer, Boston,MA,USA) for 24h asdescribed [13].
After washing twicewith PBS themacrophages were equilibrated for
18 h inRPMI 1640medium (Invitrogen, Carlsbad, CA,USA) containing% absorption ¼ [ratio 14C/3H (dosing solution) e ratio 14C/3H (sample)]1% penicillin/streptomycin and 2% bovine serum albumin (Sigma).
Immediately before injection, cells were harvested and resuspended
in RPMI 1640. As general procedure for in vivo macrophage-to-feces
RCT studies [14,15], [3H]cholesterol-loaded macrophage foam cells
were injected intraperitoneally into individually housed recipient
mice. Plasmawas collected at indicated time points aftermacrophage
injection. At the end of the experimental period, livers were har-
vested, snap-frozen in liquid nitrogen and stored at 80 C until
further use. Feces were collected as indicated up to 48 h. Counts in
plasma were assessed directly by liquid scintillation counting (Pack-
ard 1600CA Tri-Carb, Packard, Meriden, CT, USA), tracer contents of
liver and feces were assessed as indicated below. All obtained counts
were expressed relative to the administered tracer dose and are given
as a percentage of the respective controls.
Speciﬁcally, to study the effects of apoA-I on RCT, C57BL/6J mice
received rHDL (100 mg/kg apoA-I-POPC) intraperitoneally 30 min
after labeled macrophage administration. To investigate the effects
of inhibiting intestinal sterol absorption, either ezetimibe
(0.001%, w/w) or cholestyramine (2%, w/w) were mixed into the
food for 2 weeks before animals were treated with either PBS
vehicle or apoA-I-POPC as indicated.
2.4. Plasma and liver lipid analysis
Plasma total cholesterol, free cholesterol and triglycerides were
measuredenzymaticallyusingcommerciallyavailable reagents (Wako
Pure Chemical Industries, Neuss, Germany). Hepatic cholesterol con-
tent was determined with the same commercial kits following liver
tissue homogenization and lipid extraction using the general proce-
dure of Bligh and Dyer with slight modiﬁcations as described [15].
2.5. Fecal bile acid and neutral sterol analysis
Fecal samples collected over the indicated time periods were
dried, weighed and thoroughly ground. Aliquots were then used to
determine neutral sterols and bile acids by gas liquid chromatog-
raphy as described [15].
2.6. Determination of counts recovered within liver and feces
Counts within liver were determined following solubilization of
the tissue (Solvable, Packard,Meriden, CT,USA) exactlyas previously
reported [16]. Counts recovered froma respective piece of liverwere
backcalculated to total liver mass. Fecal samples were dried,
weighed and thoroughly grounded. Aliquots were separated into
bile acid and neutral sterol fractions using alkaline methanol and
petroleum ether extractions as previously published [7,14]. Counts
recovered from the respective aliquots were related to the total
amount of feces produced over the indicated experimental periods.
2.7. Determination of intestinal cholesterol absorption
A fresh mixture consisting of 1 mCi of 14C-cholesterol and 2 mCi of
3H-sitostanol in 100 ml of MCToil was administered by oral gavage to
mice. Feces were collected for 2 days, dried, weighed, and ground.
Sterols were extracted by the method of Folch and radioactivity was
determined by liquid scintillation counting. Cholesterol absorption is
calculated as follows:/[ratio 14C/3H (dosing solution)]
Table 1
Effect of a single administration of rHDL on sterols in plasma, liver, and feces.
Vehicle
n ¼ 8e14
rHDL
n ¼ 8e14
Plasma total cholesterol (mg/dl) 4 h 70  10 84  17
24 h 90  11 90  6
48 h 64  6 69  7
Plasma free cholesterol (mg/dl) 4 h 30  3 43  3***
24 h 21  3 21  2
48 h 20  2 23  3
Plasma triglycerides (mg/dl) 4 h 69  24 133  65*
24 h 85  27 69  22
24 h 67  13 56  9
Plasma human apoA-I (mg/ml) 4 h n.d. 896  298
24 h n.d. 237  74
48 h n.d. 88  26
Hepatic cholesterol content (mg) 4 h 1.41  0.10 1.42  0.14
24 h 1.44  0.10 1.41  0.11
48h 1.54  0.13 1.45  0.09
Fecal neutral sterol mass (mg) 4 h 0.354  0.245 0.422  0.188
24 h 1.393  0.505 1.438  0.562
48 h 2.624  0.675 2.557  0.622
Fecal bile acid mass (mmol) 4 h 0.418  0.164 0.492  0.278
24 h 1.266  0.461 1.321  0.560
48 h 1.585  0.257 1.700  0.274
Values are means  SEM. signiﬁcantly different from vehicle-infused controls,
*p < 0.05, ***p < 0.001.
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Statistical analysis was carried out using the Statistical Pack-
age for the Social Sciences (SPSS, Inc., Chicago, IL, USA). Values
are expressed as means  SEM. Student’s t test was used to
compare two different groups, for the comparison of multiple
groups two-way ANOVA was applied followed by Bonferroni
post-hoc test to assess statistical differences between groups.
Statistical signiﬁcance for all comparisons was assigned at
p < 0.05.Fig. 1. A single administration of rHDL increases early cholesterol appearance from macrop
(B) liver and (C) total feces as well as the fecal neutral sterol and bile acid fractions. Mice wer
macrophage-to-feces RCT studies were carried out as speciﬁed in Methods. Data are given3. Results
3.1. rHDL administration increases plasma free cholesterol levels,
but not mass fecal sterol excretion
First, the effect of a single administration of rHDL on lipid
metabolism was assessed. Early after rHDL administration (4 h)
there was a 2.5-fold increase in plasma free cholesterol levels
translating into a 34% increase in plasma total cholesterol levels in
the treatment compared with the control group (Table 1,
p < 0.001). Plasma triglycerides were also signiﬁcantly increased
in the treated versus the control group 4 h after rHDL (Table 1,
p < 0.05). Although human apoA-I was still detectable in mouse
plasma up to 48 h after administration (Table 1), at later time
points (24 h and 48 h) no changes in plasma cholesterol or tri-
glyceride levels were found. The early increase in plasma free
cholesterol levels did also not translate into changes in hepatic
cholesterol content (Table 1) or fecal mass excretion of sterols
either within the neutral sterol fraction or after metabolic con-
version to bile acids (Table 1).3.2. rHDL administration mobilizes macrophage-derived
cholesterol to plasma and increases in vivo RCT
Next we aimed to determine whether administration of rHDL
would change in vivo RCT. In agreement with the mass data, rHDL
administration resulted in a substantial increase in themobilization
of macrophage-derived cholesterol to plasma, predominantly at
earlier time points (4 h, p < 0.001; 24 h and 48 h, n.s., Fig. 1A). On
the other hand, macrophage-derived cholesterol tracer recovered
within liver at different time points did not change (Fig. 1B).
However, rHDL administration resulted in a signiﬁcant increase in
overall RCT (4e24 h, p< 0.01; 24e48 h, p< 0.05, Fig. 1C, left panel),
mainly due to a signiﬁcant increase in the fecal tracer excretion
within the neutral sterol fraction (p < 0.05, Fig. 1C, middle panel),hages in plasma and overall macrophage-to-feces RCT. Tracer recovery in (A) plasma,
e either administered a single dose of rHDL (100 mg/kg of apoA-I-POPC) or vehicle, and
as means  SD, n ¼ 8e14 mice/group. *p < 0.05, **p < 0.01, ***p < 0.001.
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but not signiﬁcantly altered (Fig. 1C, right panel).
3.3. Metabolic effects of rHDL administration on top of treatment
with ezetimibe or cholestyramine
Since inhibiting the reabsorption of biliary secreted sterols from
the intestinal lumen might represent a viable clinical strategy to
increase RCT, we next explored the metabolic effects of rHDL
administration in mice that had been fed either the cholesterol
absorption inhibitor ezetimibe or the bile acid sequestrant chole-
styramine. Ezetimibe as well as cholestyramine treatment did not
change baseline levels of plasma free or total cholesterol (Fig. 2A
and B) as well as triglycerides (Fig. 2C). However, administration of
rHDL resulted in an early (4 h) increase in plasma free cholesterolFig. 2. Effects of a single administration of rHDL (100 mg/kg of apoA-I-POPC) on top of ezet
(C) triglycerides. Mice were fed either chow (con) or chow supplemented with ezetimibe (ez
single injection with rHDL or vehicle alone were assessed. Data are given as means  SD, nlevels in the control and the ezetimibe-administered mice
(p < 0.001, Fig. 2A), while there was a decrease in mice on chole-
styramine (p < 0.001, Fig. 2A). At later time points, only
cholestyramine-treated mice had increased plasma free cholesterol
levels in response to the rHDL administration (24 h, p < 0.01, 48 h,
p< 0.001, Fig. 2A). Plasma total cholesterol levels largely changed in
the same direction as detailed above due to the respective changes
in plasma free cholesterol levels (Fig. 2B). Plasma triglycerides were
increased in all groups in response to rHDL administration after 4 h
(at least p < 0.05, Fig. 2C), but not at subsequent time points. FPLC
analysis (Supplemental Fig.1) showed increases in VLDL cholesterol
corresponding to the increase in triglycerides at 4 h and no changes
in the proﬁles at 48 h. The concentration of plasma human apoA-I
after administration of rHDL was similar in all treatment groups
(Supplemental Fig. 2). No differences were observed in hepaticimibe and cholestyramine on (A) plasma free cholesterol, (B) plasma total cholesterol,
e, 0.001%, w/w) or cholestyramine (chol, 2%, w/w) for 14 days, and then the effects of a
¼ 6e8 mice/group. *p < 0.05, **p < 0.01, ***p < 0001.
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mice treated with ezetimibe, mass fecal neutral sterol excretion
was substantially higher at all time points investigated (p < 0.001,
Fig. 3B) due to a signiﬁcant 74% decrease in intestinal cholesterol
absorption as determined by the dual isotope method (p < 0.01,
data not shown). Fecal bile acid excretion was not affected by
ezetimibe (Fig. 3C). In contrast, cholestyramine administration
signiﬁcantly increased, as expected, fecal bile acid excretion several
fold during all sampling periods (p < 0.001, Fig. 3C). Surprisingly,
also fecal excretion of neutral sterols was higher than in controls
(0e4 h and 24e48 h, p< 0.001; 4e24 h, p< 0.01, Fig. 3B). Intestinal
absorption studies conﬁrmed that this effect related to a signiﬁcant
24% decrease in cholesterol absorption in cholestyramine-
administered mice (p < 0.01, data not shown). Although not pre-
viously reported, these results are plausible given the key role that
bile acids play in cholesterol absorption. However, administrationFig. 3. Effects of a single administration of rHDL (100 mg/kg of apoA-I-POPC) on top of eze
excretion, and (C) fecal bile acid excretion. Mice were fed either chow (con) or chow supplem
and then the effects of a single injection with rHDL or vehicle alone were assessed. Data aof rHDL only resulted in an early increase in fecal neutral sterol
excretion (0e4 h) in the control group (p< 0.05, Fig. 3B) and in fecal
bile acid excretion (0e4 h and 4e24 h) in the cholestyramine group
(each p< 0.05, Fig. 3C), but had otherwise no discernable effects on
fecal mass sterol excretion.
3.4. Ezetimibe and cholestyramine both increase macrophage-to-
feces RCT in vivo, but administration of rHDL has no additive effect
To investigate, if the mass changes in fecal sterol excretion in
response to inhibiting intestinal sterol absorption would also
translate into altered RCT, macrophage-to-feces RCT studies were
performed. Both, ezetimibe and cholestyramine treatment left the
appearance of macrophage-derived counts in plasma essentially
unaltered throughout the experiment (Fig. 4A). Administration of
rHDL signiﬁcantly increased the early (4 h) mobilization of thetimibe and cholestyramine on (A) hepatic cholesterol content, (B) fecal neutral sterol
ented with ezetimibe (eze, 0.001%, w/w) or cholestyramine (chol, 2%, w/w) for 14 days,
re given as means  SD, n ¼ 6e8 mice/group. *p < 0.05, **p < 0.01, ***p < 0001.
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all groups ofmice (p< 0.05, Fig. 4A), while therewere no discernible
effects at later time points. Counts recovered within liver at 48 h
were increased upon rHDL administration without any other
treatment (p < 0.01, Fig. 4B), but otherwise none of the treatments
had signiﬁcant effects on the hepatic content of the macrophage-
derived cholesterol tracer (Fig. 4B). On the other hand, fecal tracer
output indicating completed overall RCTwas signiﬁcantly increased
in ezetimibe-treated mice by 2.7-fold in the 4e24 h period
(p< 0.001, Fig. 4C) and by 2.1-fold in the 24e48 h period (p< 0.001,
Fig. 4C). Also in mice administered cholestyramine, fecal tracer
excretion from 4 to 24 h (2.2-fold, p < 0.001) as well as from 24 to
48 h (3.6-fold, p < 0.001) was signiﬁcantly increased (Fig. 4C).
Interestingly, fecal tracer output was in the 24e48 h period even
higher in the cholestyramine than in the ezetimibe receiving mice
(p<0.01, Fig. 4C). However, although rHDLadministration increased
RCT in otherwise untreatedmice (p< 0.05, Fig. 4C), this intervention
had no signiﬁcant additional effect on the fecal excretion of the
macrophage-derived tracer either in the ezetimibe- or the
cholestyramine-treated groups (Fig. 4C).Fig. 4. Ezetimibe and cholestyramine both substantially increase macrophage-to-feces RCT b
supplemented with ezetimibe (eze, 0.001%, w/w) or cholestyramine (chol, 2%, w/w) for 14 d
alone as indicated. Then macrophage-to-feces RCT studies were carried out as speciﬁed in M
neutral sterols, and (E) fecal bile acids. Data are given as means  SD, n ¼ 6e8 mice/groupNext, we also differentiated between fecal tracer excretion
within neutral sterols and bile acids. As shown in Fig. 4D ezeti-
mibe had a major effect on the fecal output of macrophage-
derived cholesterol within the neutral sterol fraction from 4 to
24 h (11-fold, p < 0.01) and 24e48 h (5.3-fold, p < 0.001, Fig. 4D),
while, consistent with the data on intestinal cholesterol absorp-
tion, the increase in fecal tracer excretion within neutral sterols
was less in cholestyramine-treated mice (4e24 h, p < 0.05; 24e
48 h, p < 0.001, Fig. 4D), but still substantially higher compared
with controls at 48 h (2-fold, p < 0.001, Fig. 4D). On the contrary,
inhibiting intestinal bile acid absorption with cholestyramine
increased fecal tracer excretion within the bile acid fraction by
3.9-fold from 4 to 24 h (p < 0.001 to all other groups, Fig. 4E) and
3.2-fold from 24 to 48 h (p < 0.001 to all other groups, Fig. 4E),
while ezetimibe had no signiﬁcant effect (Fig. 4E). Administration
of rHDL increased fecal tracer excretion within neutral sterols
and bile acids in the controls (each p < 0.05 from 4 to 24 h and
p < 0.01 from 24 to 48 h, Fig. 4E), but had no signiﬁcant addi-
tional effect on RCT in the ezetimibe or cholestyramine treatment
groups.ut administration of rHDL has no additional effect. Mice were fed either chow or chow
ays, and injected with a single dose of either rHDL (100 mg/kg apoA-I-POPC) or vehicle
ethods. Tracer recovery is shown in (A) plasma, (B) liver and (C) total feces, (D) fecal
. *p < 0.05, **p < 0.01, ***p < 0001.
Fig. 4. (Continued).
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The results of this study demonstrate that (i) stimulating the
initial step of RCT by a single administration of rHDL results in an
early rapid mobilization of cholesterol frommacrophage foam cells
to plasma, (ii) stimulating the last step of RCT by sterol absorption
inhibitor treatment (ezetimibe or cholestyramine) signiﬁcantly
increases RCT, and (iii) inhibiting intestinal sterol uptake has no
apparent additional efﬁcacy on top of rHDL.
Initial clinical studies including a limited number of patients with
acute CVD [17] aswell as patientswith stable atherosclerotic CVD [18]
indicated that infusing rHDL could be a viable strategy to decrease
clinical symptoms as well as atherosclerotic lesion size. Our data
provide a mechanistic basis for these ﬁndings by showing that an
acute administration of rHDL results in rapid mobilization of choles-
terol frommacrophage foam cells to the plasma compartment. Given
thatmacrophage foamcells are thehallmarkof atherosclerotic lesions
in general [2,3] and of unstable lesions in particular [3,19], effective
mobilization of cholesterol speciﬁcally from this cell type would be
expected to have beneﬁcial effects. In addition, it has recently been
shown that unloading of cholesterol causes macrophages to migrate
out of atherosclerotic lesions and towards regional lymph nodes
[20,21]. Via this mechanism cholesterol unloading could actually
further reduce the number of macrophages within lesions, thereby
contributing to stabilization or even regression of the lesion, although
this concept was not speciﬁcally tested in the current study.
Since rHDL administration is thus far considered a rather acute
therapeutic option, we further explored, if rHDL administration
would have an additive effect over treatment with ezetimibe and
cholestyramine, known inhibitors of intestinal cholesterol and bile
acid absorption, respectively. Ezetimibe blocks NPC1L1 and thereby
intestinal cholesterol absorption resulting in increased fecal neutral
sterol excretion and atheroprotection, at least in animal models
[22,23]. In addition to these features ezetimibe was previouslyshown to increase macrophage-to-feces RCT [24,25], which was
conﬁrmed by our present data.
In contrast, the impact of inhibiting bile acid absorption on RCT
has not been addressed, yet. Cholestyramine is a bile acid binding
resin that inhibits intestinal bile acid absorption leading to increased
fecal bile acid excretion and in turn increased bile acid synthesis
from cholesterol [26]. Apparently, this is resulting in an increased
ﬂux through the different compartments of cholesterolmetabolism,
since cholesterol mobilized by rHDL is rapidly removed from the
circulation as indicated by a decrease in plasma cholesterol levels in
the cholestyramine-treatedmice. Bile acid binding resins have been
proven effective to reduce atherosclerosis in animal models as well
as CVD events in clinical outcome studies in patients [26e28]. An
unexpected ﬁnding of our present study was that cholestyramine
did not only increase the fecal excretion of bile acids but also of
cholesterol mass. Given the important role of mixed micelles in
intestinal cholesterol absorption [29], decreasing the availability of
intestinal bile acids for micelle formation might conceivably
represent the underlyingmechanism for cholestyramine to increase
fecal neutral sterol excretion. These dual properties of cholestyr-
amine translated directly into a substantial increase inmacrophage-
to-feces RCT by enhancing fecal tracer output within bile acids but
also within neutral sterols. Interestingly, the overall stimulating
effects of cholestyramine onRCTwere even signiﬁcantly higher than
the impact of ezetimibe on RCT.
Our data indicate that RCT can be substantially increased by
targeting the intestinal compartment, namely by blocking the
reabsorption of sterols. Thereby, the intestine represents an organ
that appears quantitatively of high importance for RCT. These
properties might be amajor underlying unifyingmechanism for the
action and anti-atherosclerotic efﬁcacy of both ezetimibe and
cholestyramine. However, when co-administered with rHDL eze-
timibe or cholestyramine did not impact the early mobilization of
macrophage cholesterol to plasma.
C. Maugeais et al. / Atherosclerosis 229 (2013) 94e101 101The in vivo RCT assay used in the present study is a surrogate
approach for vessel wall macrophages. The results therefore likely
reﬂect relevant pathophysiological events. However, a potential
limitation of this method is that the labeled macrophages are
injected i.p. and might not reﬂect accurately the endogenous
cholesterol ﬂux from extra-hepatic tissue to the liver. Furthermore,
in contrast to humans, mice do not express CETP. In our model rHDL
acts additive to intestinal sterol absorption inhibitors, but not
synergistic. The effect of the rHDL-driven increase in RCT is quan-
titatively minor compared to the overall impact of ezetimibe or
cholestyramine, and in the context of adding rHDL to these treat-
ments, the signiﬁcance of the biological effect is lost. CETP partic-
ipates in RCT by transferring cholesterol from HDL to LDL for
subsequent uptake by the liver via LDL receptor and sterol ab-
sorption inhibitors result in an upregulation of LDL receptors.
Thereby the lack of a synergistic effect of rHDL and cholestyramine/
ezitimibe treatment on RCT observed in the present study might be
due to the lack of CETP in our model.
In all treatment groups, administration of rHDL resulted in an
early increase in plasma VLDL cholesterol and triglyceride levels, an
observation that has already been made earlier in studies using
rHDL [30e32]. Mechanistically, this has been attributed to a dose-
dependent inhibition of LPL activity by rHDL [31].
In summary, the results of this study demonstrate that (i) rHDL
administration is effective in acutely stimulating RCT and (ii) both
ezetimibe and cholestyramine signiﬁcantly enhance RCT. However,
the two respective approaches target different steps of the RCT
pathwayanddemonstrateminimal additiveeffects inwild-typemice.
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